June 25, 2005

License Holds Promise For Schizophrenia?

Read more... Schizophrenia Biology

INTRA-CELLULAR THERAPIES, INC.; Company receives license for central nervous system compounds

Intra-Cellular Therapies, Inc., (ITI) a privately held biopharmaceutical company focusing on the development of new therapeutics for neuropsychiatric and neurodegenerative disorders, announced that it has been granted an exclusive, worldwide license to a family of pre-clinical compounds from Bristol-Myers Squibb Company.

This license will "provide ITI with a portfolio of compounds." This means that ITI may soon have new treatments that are useful for schizophrenia, bipolar disorder, and even obsessive-compulisve disorder. "The compounds complement our internal pipeline of small molecule therapeutics developed using ITI's drug discovery platform," said Sharon Mates, PhD, and CEO of ITI.

Full Story:


Post a comment

Please enter this code to enable your comment -
Remember Me?
(you may use HTML tags for style)
* indicates required